Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 Analysis summary4-Traders Strategies

Jordan Dufee

 
 
share with twitter share with LinkedIn share with facebook
share via e-mail

Good timing to go long again

Strategy published on 11/17/2017 | 09:35
long trade
Live
Entry price : 75.94€ | Target : 81.4€ | Stop-loss : 73.8€ | Potential : 7.19%
The technical support around 75.58 EUR emanating from daily closing prices could trigger a technical rebound for Sanofi shares.
Investors have an opportunity to buy the stock and target the € 81.4.
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
Strengths
  • The share is getting closer to its long-term support in weekly data, at EUR 74.39, which offers good timing for buyers.
  • The close medium term support offers good timing for purchasing the stock.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • The company is in a robust financial situation considering its net cash and margin position.
  • Its low valuation, with P/E ratio at 12.15 and 16.16 for the ongoing fiscal year and 2018 respectively, makes the stock pretty attractive with regard to earnings multiples.
  • The company is one of the best yield companies with high dividend expectations.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
  • According to forecast, a sluggish sales growth is expected for the next fiscal years.
  • The group usually releases earnings worse than estimated.
  • Revenue estimates are regularly revised downwards for the current and coming years.
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
SANOFI-1.91%112 309
JOHNSON & JOHNSON20.74%373 077
NOVARTIS10.73%218 225
PFIZER8.87%211 963
ROCHE HOLDING LTD.-2.06%200 423
MERCK AND COMPANY-6.91%150 468
AMGEN15.85%123 964
BAYER8.85%105 352
BRISTOL-MYERS SQUIBB COMPAN..4.50%101 263
NOVO NORDISK A/S23.16%99 561
ABBOTT LABORATORIES42.75%96 673
ELI LILLY AND COMPANY11.75%91 875
GLAXOSMITHKLINE-15.62%85 748
ASTRAZENECA12.92%83 533
CELGENE CORPORATION-13.31%81 369
ALLERGAN PLC-17.60%58 139
More Results
Financials (€)
Sales 2017 35 939 M
EBIT 2017 9 366 M
Net income 2017 7 904 M
Debt 2017 4 659 M
Yield 2017 4,02%
P/E ratio 2017 12,15
P/E ratio 2018 16,16
EV / Sales 2017 2,78x
EV / Sales 2018 2,72x
Capitalization 95 278 M
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes
Chart SANOFI
Duration : Period : Day
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Duration : Period : Week
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders